EcoDrugPlus

Ribosomal Protein S9

Ensembl ID : ENSELUG00000015000
Gene Symbol: RPS9
3 Cross references
237 Possible Orthologues:

Ribosomal Protein Lateral Stalk Subunit P0

Ensembl ID : ENSELUG00000023779
Gene Symbol: RPLP0
3 Cross references
403 Possible Orthologues:

Ribosomal Protein Lateral Stalk Subunit P1

Ensembl ID : ENSELUG00000030035
Gene Symbol: RPLP1
3 Cross references
386 Possible Orthologues:

Serine/threonine-Protein Kinase D3

Ensembl ID : ENSELUG00000002900
Gene Symbol: LOC105015789
2 Cross references
218 Possible Orthologues:

Serine/threonine-Protein Kinase Pim-3

Ensembl ID : ENSELUG00000016851
Gene Symbol: LOC105030728
3 Cross references
178 Possible Orthologues:

Serpin Peptidase Inhibitor, Clade C (Antithrombin), Member 1

Ensembl ID : ENSELUG00000003491
Gene Symbol: SERPINC1
1 Cross references
202 Possible Orthologues:

Serum Amyloid P-Component

Ensembl ID : ENSELUG00000000614
Gene Symbol: LOC105030302
2 Cross references
348 Possible Orthologues:

Serum Amyloid P-Component-Like

Ensembl ID : ENSELUG00000016176
Gene Symbol: LOC105030303
3 Cross references
348 Possible Orthologues:

Si:dkey-211g8.6

Ensembl ID : ENSELUG00000026170
Gene Symbol: SI:DKEY-211G8.6
1 Cross references
319 Possible Orthologues:

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSELUG00000030560
Gene Symbol: SIGMAR1
3 Cross references
206 Possible Orthologues:

Sirtuin 1

Ensembl ID : ENSELUG00000021210
Gene Symbol: SIRT1
3 Cross references
159 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSELUG00000023107
Gene Symbol: SMO
3 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).